抑制Mss51蛋白质是2型糖尿病的新目标:一个分子对接和模拟研究
Shahid Ali1,2, Khurshid Ahmad1,2, Sibhghatulla Shaikh1,2
1Department of Medical Biotechnology, Yeungnam University, Gyeongsan, South Korea.
Journal of biomolecular structure & dynamics
|June 20, 2023
概括
肌静素抑制会影响肌肉生长和新陈代谢. 研究人员确定了可能抑制Mss51的化合物,Mss51是肌肉代谢的关键因素,为肥胖和2型糖尿病提供了潜在的治疗方法.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肌平素是骨肌肉质量和新陈代谢的关键调节剂.
- 在小鼠中抑制肌态素可以改善胰岛素敏感性,并减少身体脂肪.
- 通过肌素抑制降低调控的Mss51与骨肌肉代谢健康和脂肪组织减少有关,使其成为肥胖和2型糖尿病的治疗点.
研究的目的:
- 通过计算预测和验证Mss51.1.的3D结构.
- 通过计算选来识别抑制Mss51的天然化合物.
- 评估已识别的化合物的结合稳定性和治疗潜力.
主要方法:
- 计算预测和验证Mss51的3D结构.
- 对Mss51抑制剂的Herbal and Specs化学数据库进行虚拟选.
- 分子动力学模拟以评估化合物-Mss51相互作用和结合稳定性.
主要成果:
- 获得了Mss51的验证的3D结构.
- 三种化合物 (ZINC00338371,ZINC95099599,ZINC08214878) 显示出对Mss51的高结合亲和力和特异性.
- 分子动力学模拟证实了化合物与Mss51的活性部位的稳定结合,其中ZINC00338371表现出最稳定的相互作用.
结论:
- Mss51是代谢障碍的一个有前途的治疗点.
- ZINC00338371显示出作为治疗肥胖和2型糖尿病的治疗剂的巨大潜力,这是由于其稳定结合Mss51.1.
关键词:
模拟MDMD的模拟在Mss51中,我们可以看到Mss51.脂质生成 (adipogenesis) 是一种肌肉发育 (myogenesis) 是一个过程.自然化合物 自然化合物2 型糖尿病 2 型糖尿病更多相关视频
10:21Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
Published on: February 23, 2024
2.7K
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
390
相关概念视频
02:04Protein-protein Interfaces
12.6K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.6K
01:23Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216